BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frimat L, Mariat C, Landais P, Koné S, Commenges B, Choukroun G. Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open 2013;3:e001888. [PMID: 23474787 DOI: 10.1136/bmjopen-2012-001888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Chan K, Li C, Wong H, Yip T, Sham M, Cheng H, Teo K, Kwok W, Chan T. Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients. Int Urol Nephrol 2014;46:653-7. [DOI: 10.1007/s11255-014-0661-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Joré C, Brun JF, Varlet-Marie E. Rise in RBC aggregability and concomitant decrease in blood pressure 10 days after injection of the long acting erythropoietin analogue methoxy polyethylene glycol-epoetin-β (MIRCERA®). Clin Hemorheol Microcirc 2016;64:809-16. [PMID: 27767968 DOI: 10.3233/CH-168015] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 2019;14:93-126. [PMID: 30451076 DOI: 10.2217/nnm-2018-0120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 100] [Article Influence: 35.8] [Reference Citation Analysis]
4 Üstündağ S, Doğan E, Duranay M, Kazancıoğlu R, Çelik V, Ünsal A, Altıntepe L, Dursun B, Akbaş E, Özdener F, Yıldız A. Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients. Balkan Med J 2016;33:322-30. [PMID: 27308077 DOI: 10.5152/balkanmedj.2016.141173] [Reference Citation Analysis]
5 Tsuruya K, Uemura Y, Hirakata H, Kitazono T, Tsubakihara Y, Suzuki M, Ohashi Y. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton) 2017;22:769-75. [PMID: 27312361 DOI: 10.1111/nep.12842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Cases A, Portolés J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Int Urol Nephrol 2014;46:1983-95. [PMID: 25118611 DOI: 10.1007/s11255-014-0800-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Martínez-Castelao A, Cases A, Carballada AT, Iranzo JT, Bronsoms J, Vallès-Prats M, Monserrat DT, Jimenez EM; investigators of the ACERCA Study Group. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study. Nefrologia 2015;35:179-88. [PMID: 26300512 DOI: 10.1016/j.nefro.2015.05.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Vigneau C, Choukroun G, Isnard-Bagnis C, Pau D, Sinnasse-Raymond G, Pibre S, Moranne O. "Doctor, can I have less frequent injection with highly efficient treatment?" A patient centered study using an electronic choice-based conjoint analysis (ePRO) to assess real world preferences regarding erythropoiesis stimulating agent to treat anaemia in chronic kidney disease (PERCEPOLIS study). Nephrol Ther 2019;15:152-61. [PMID: 30962139 DOI: 10.1016/j.nephro.2018.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]